Antiretroviral injection gives viral suppression for 17 months

29 January 2016

injecting.jpg

Doctor injecting patient with gloves on

A once-a-week injection that can offer ‘complete viral-load suppression’ for up to 17 months, could be available from 2017 according to Pharmaceutical company CytoDyn Inc. following a trial of 23 patients.

According to the company announcement (19 January 2016), the results of an ongoing extension study of the drug PRO 140 monotherapy means that, with more successful trials, the treatment could present a ‘significant opportunity' to treat those living with HIV

A weekly injection would replace the need for daily antiretroviral treatment (ART) pills, tackling issues of adherence and drug interaction.

Dr. Nader Pourhassan, CytoDyn’s President and CEO commented that: “Only about 25% of HIV patients in the U.S. have a completely suppressed viral load. A large contributor to this problem is due to patients’ inability to adhere to a highly structured schedule to take their medications on a specific timetable every day of their lives. PRO 140 […] could be the solution to this very serious adherence problem.

“Moreover, our clinical trials to date have clearly indicated that PRO 140 is safe and efficacious without the side effects and toxicities experienced in the current ART therapeutic regimen. We are optimistic about our current and upcoming trials of PRO 140 and believe our antibody presents a compelling alternative or adjunct therapy to ART for HIV patients.”

Based on these results, the company plans to file a second Phase III protocol for PRO 140 monotherapy with the US Food and Drug Administration (FDA).

Earlier this month, AVERT reported on another successful trial of injectable HIV treatment by specialist HIV company, ViiV Healthcare, and Janssen Sciences Ireland UC (Janssen). The Phase II trial found the injectable therapy, taken every one or two months, to be just as effective as those who took a ‘daily oral regimen’. 

Photo credit:
©iStock/ annebaek

Community guidelines for comments can be found in our website T&Cs